arrow_back Back to App

Biomedical Innovation Fund: Boosting Medical Research Funding

This act establishes a special fund that will annually inject $10 billion into medical research in the U.S. These funds are intended to support the development of new drugs and therapies, and to help combat diseases that place the greatest burden on the healthcare system. As a result, citizens can expect faster access to innovative treatments and improved healthcare.
Key points
A Biomedical Innovation Fund is established, receiving $10 billion annually until 2030.
Funds will go to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) to support disease research and medical product development.
Money will be used for basic research, disruptive innovation (e.g., chronic pain), diseases disproportionately impacting federal healthcare spending, early career scientists, and diversity in research.
The fund aims to accelerate medical discoveries and improve access to modern treatments for citizens.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_2187
Sponsor: Sen. Warren, Elizabeth [D-MA]
Process start date: 2021-06-23
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

National Biomedical Research Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_2187.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-06-23.

What are the main provisions?

Key points include:

  • A Biomedical Innovation Fund is established, receiving $10 billion annually until 2030.
  • Funds will go to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) to support disease research and medical product development.
  • Money will be used for basic research, disruptive innovation (e.g., chronic pain), diseases disproportionately impacting federal healthcare spending, early career scientists, and diversity in research.
  • The fund aims to accelerate medical discoveries and improve access to modern treatments for citizens.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Warren, Elizabeth [D-MA].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health Public Investments